Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Lebanon Substitution Drug List

 
According to the Law No. 91 issued on 2010 related to the Pharmacist substitution right, the Ministry of Public Health conceived the Substitution Drug list. It is presented as a scientific, objective, reliable, accurate and accessible listing. This list is a helpful tool for Pharmacists and Health professionals and an information tool for patients as well.

The Substitution Drug List was compiled by a team of Pharmacists and Physicians from the Ministry of Public Health. It was inspired by the French Repertory of Generic Groups and the Lebanese National Drug Index (LNDI) which is the reference Guide for medicines in Lebanon.

The substitution could be done between an innovator product and a generic, based on the Ministry of Public Health Substitution list, providing that the product delivered is cheaper and has obtained the patient’s consent.

This Substitution Drug List, lists drugs, dosage forms, package sizes, drug strengths and other information registered at the Ministry of Public Health. It is divided into sections based on the Anatomical Therapeutic Chemical (ATC) classification system. The Innovator product is listed before the Generic products.

Information is shown in a convenient format with trade information in italics:
 
  ATCcode          
  Trade Name & Strength   B=Brand
G=Generic
 
  Route Form Container Presentation Code MOPH Registration Number at MOPH
    Active Ingredients with their respective dosage    
    Agent importing product Manufacturer Country of Origin  
        Responsible Party Country of Responsible Party
Each medication listing contains the following information:
  • ATC classification and code.
  • Trade name and strength of the formulation as registered at the Ministry of Public Health (MOH)
  • Generic (G) or Brand product (B)
  • Composition of the marketed form with the corresponding dosage of each active ingredient.
  • Form &presentation.
  • The local importer (agent), manufacturer and identified country of origin.
  • The Responsible Party and identified country.
  • The Ministry of Public Health database serial number (Code MOH) and legal registration document number (MOH reg)
 
The Substitution Drug List can be accessed from the official website of the Ministry of Public Health: www.moph.gov.lb

The Substitution Drug List welcomes comments from healthcare professionals. Please send comments to: [email protected]
 
 
Lebanon Substitution Drug List - First Edition 2015 (Revised)
    ...
    52
    ...
ATC Name B/G Ingredients Dosage Form Price
J01CR05 PRIZMA G Piperacillin (sodium) - 4g, Tazobactam (sodium) - 0.5g Injectable powder for solution 913,813 L.L
G04BX14 PRIXETIN 60 G Dapoxetine (hydrochloride) - 60mg Tablet, film coated 1,479,123 L.L
G04BX14 PRIXETIN 30 G Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 2,105,353 L.L
R05DB21 PRIVITUSS G L-Cloperastine - 708mg/100ml 708mg/100ml Suspension 801,186 L.L
J06BA02 PRIVIGEN BioHuman Immunoglobulin human - 5g/50ml 10% Injectable solution 44,463,925 L.L
J07BD52 PRIORIX B Rubella virus live attenuated - ?10³ CCID50, Mumps virus live attenuated - ?103.7 CCID50, Measles virus live attenuated - ?10³ CCID50 Injectable lyophilised powder for solution+diluent 1,142,266 L.L
G03DC02 PRIMOLUT NOR B Norethisterone acetate - 5mg 5mg Tablet 296,989 L.L
A02BC05 PRIMAZOL 40 G Esomeprazole (magnesium dihydrate) - 40mg 40mg Capsule, gastro-resistant 639,925 L.L
A02BC05 PRIMAZOL 20 G Esomeprazole (magnesium dihydrate) - 20mg 20mg Capsule, gastro-resistant 511,940 L.L
A03CA02 PRIMAX G Clidinium bromide - 2.5mg, Chlordiazepoxide - 5mg Tablet 222,694 L.L
M01AB05 PRIMAFENAC G Diclofenac sodium - 50mg 50mg Tablet, enteric coated 223,974 L.L
G04BX14 PRILIGY B Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 1,957,979 L.L
G04BX14 PRILIGY B Dapoxetine (hydrochloride) - 60mg 60mg Tablet, film coated 1,957,979 L.L
N01BB54 PRILA G Prilocaine - 2.5% w/w, Lidocaine - 2.5% w/w Cream 1,057,604 L.L
N01BB54 PRILA G Prilocaine - 2.5% w/w, Lidocaine - 2.5% w/w Cream 1,163,768 L.L
N05AH03 PREXAL 5 G Olanzapine - 5mg 5mg Caplet, film coated 718,956 L.L
N05AH03 PREXAL 10 G Olanzapine - 10mg 10mg Caplet, film coated 881,561 L.L
J05AX18 PREVYMIS B Letermovir - 240mg 240mg Tablet, film coated 460,943,945 L.L
J05AX18 PREVYMIS B Letermovir - 480mg 480mg Tablet, film coated 961,233,292 L.L
J05AX18 PREVYMIS B Letermovir - 240mg/12ml 240mg/12ml Injectable concentrate for solution 23,599,640 L.L
J07AL02 PREVENAR 20 B Pneumococcal polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F,8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F,22F, 23F, 33F (2.2mcg) Pneumococcal polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein (approximately 51mcg) adsorbed on aluminium phosphate (0.125mg aluminium) - Injectable suspension 7,415,107 L.L
J07AL02 PREVENAR 13 B Polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F, 9V,14, 18C, 19A, 19F, 23F (2.2mcg)Polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate (0.125mg aluminium) - Injectable suspension 6,352,343 L.L
C09BA04 PRETERAX ARGININE B Perindopril arginine - 2.5mg, Indapamide - 0.625mg Tablet, film coated 452,875 L.L
C09BB04 PRESORYL PLUS G Perindopril arginine - 5mg, Amlodipine (besylate) - 5mg Tablet 557,695 L.L
C09BB04 PRESORYL PLUS G Perindopril arginine - 10mg, Amlodipine (besylate) - 5mg Tablet 770,022 L.L
C09BB04 PRESORYL PLUS G Perindopril arginine - 10mg, Amlodipine (besylate) - 10mg Tablet 770,022 L.L
D07AC14 PRENIDERM G Methylprednisolone aceponate - 0.1% 0.1% Cream 312,283 L.L
N02BF02 PREGASTAR G Pregabalin - 75mg 75mg Capsule, hard 653,370 L.L
N02BF02 PREGABADOR G Pregabalin - 75mg 75mg Capsule, hard 364,181 L.L
H02AB06 PREDOXONE G Prednisolone sodium phosphate - 15mg/5ml 15mg/5ml Solution 417,231 L.L
    ...
    52
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025